NEW DELHI: The Indian Council of Medical Research has issued revised guidelines for Covid-19 in view of the spurt in cases in the last one week across the country.
“The guideline does not advise Use Lopinavir-ritonavir, HCQ, ivermectin, convalescent plasma, molanupiravir, favipiravir, azithromycin, doxycycline,” Dr. tweeted Lokesh Sharma, Heath Informatics Researcher, ICMR.
“Antibiotics should not be used unless there is clinical suspicion of bacterial infection. The possibility of co-infection of COVID with other endemic infections should be considered. Systemic corticosteroids indicated in mild illness is not given,” the revised guidelines said.
“Seek immediate medical attention if you have difficulty breathing, high-grade fever/severe cough, especially for more than five days. A lower limit should be kept for those with any high-risk characteristic,” the guidelines further said. Additionally, in moderate or severe disease with a high risk of progression, the guidelines recommend, “consider remdesivir for up to five days (200 mg IV OD on day 1 followed by 100 mg IV OD for the next four days)”.
Last week, the Union Health Ministry wrote to the state governments of Maharashtra, Gujarat, Telangana, Tamil Nadu, Kerala and Karnataka to follow the five-fold strategy of Test, Track, Treat and Vaccinate as these states saw a surge in Covid-19 Is going cases,
“The guideline does not advise Use Lopinavir-ritonavir, HCQ, ivermectin, convalescent plasma, molanupiravir, favipiravir, azithromycin, doxycycline,” Dr. tweeted Lokesh Sharma, Heath Informatics Researcher, ICMR.
“Antibiotics should not be used unless there is clinical suspicion of bacterial infection. The possibility of co-infection of COVID with other endemic infections should be considered. Systemic corticosteroids indicated in mild illness is not given,” the revised guidelines said.
“Seek immediate medical attention if you have difficulty breathing, high-grade fever/severe cough, especially for more than five days. A lower limit should be kept for those with any high-risk characteristic,” the guidelines further said. Additionally, in moderate or severe disease with a high risk of progression, the guidelines recommend, “consider remdesivir for up to five days (200 mg IV OD on day 1 followed by 100 mg IV OD for the next four days)”.
Last week, the Union Health Ministry wrote to the state governments of Maharashtra, Gujarat, Telangana, Tamil Nadu, Kerala and Karnataka to follow the five-fold strategy of Test, Track, Treat and Vaccinate as these states saw a surge in Covid-19 Is going cases,
